2-methyl-N-propan-2-ylprop-1-en-1-amine | 65500-35-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-methyl-N-propan-2-ylprop-1-en-1-amine
• CAS: 65500-35-8
• 化学式: C₇H₁₅N
• 分子量: 113.203
• InChiKey: FGUSCZIWUKWPFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-N-propan-2-ylprop-1-en-1-amine 、 丙烯腈 生成 (5E)-4,4-Dimethyl-5-[(propan-2-yl)imino]pentanenitrile
  参考文献：
  名称：

  仲烯胺的制备，表征和某些性能

  摘要：

  亚胺的有机锡或镁盐的部分甲醇分解产生仲烯胺，该仲烯胺在非质子介质中稳定，从而可以研究其物理和化学性质。

  DOI：

  10.1039/c39770000565
• 作为产物：
  描述：

  2-methyl-N-propan-2-yl-N-tributylstannylprop-1-en-1-amine 在 甲醇 作用下， 生成 2-methyl-N-propan-2-ylprop-1-en-1-amine
  参考文献：
  名称：

  仲烯胺的制备，表征和某些性能

  摘要：

  亚胺的有机锡或镁盐的部分甲醇分解产生仲烯胺，该仲烯胺在非质子介质中稳定，从而可以研究其物理和化学性质。

  DOI：

  10.1039/c39770000565

文献信息

• NOVEL QUINOLINE -SUBSTITUTED COMPOUND
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160194332A1

  公开（公告）日：2016-07-07

  An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.

  本发明的目标是提供一种具有EGFR抑制作用和细胞生长抑制作用的新化合物，以及一种基于EGFR抑制作用的用于预防和/或治疗癌症的药物。本发明提供以下式（I）所代表的化合物或其盐。
• POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
  申请人：Johns Brian Alvin

  公开号：US20120115875A1

  公开（公告）日：2012-05-10

  The present invention is to provide a novel compound (I) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z 1 is NR 4 ; R 1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO 2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R 2 is optionally substituted aryl; R 3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R 4 and Z 2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.

  本发明提供了一种新型化合物（I），其具有抗病毒活性，特别是HIV整合酶抑制活性，以及含有该化合物的药物，特别是抗HIV药物，以及其制备方法和中间体。（其中Z1为NR4；R1为氢或低碳基；X为单键，从O、S、SO、SO2和NH中选择的杂原子基团，或低碳基或低碳烯基，其中杂原子基团可以介入；R2为可选取代芳基；R3为氢、卤素、羟基、可选取代的低碳基等；R4和Z2共同形成环，形成多环化合物，包括三环或四环化合物等。）
• HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS
  申请人：Nanjing Allgen Pharma Co., Ltd.

  公开号：US20140322229A1

  公开（公告）日：2014-10-30

  The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.

  本文件描述了I式化合物、包含该化合物的药物组合物以及使用该化合物治疗癌症、神经疾病、神经退行性疾病、中风、创伤性脑损伤、寄生虫感染、炎症或自身免疫性疾病的方法。
• CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
  申请人：Knoller Helmut

  公开号：US20130217871A1

  公开（公告）日：2013-08-22

  The present invention relates to hydroxyalkyl starch conjugates and a method for preparing the same, the hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one primary hydroxyl group, wherein the hydroxyalkyl starch is linked via said primary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS′(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold and a molar substitution (MS) in the range of from 0.6 to 1.5.

  本发明涉及羟基烷基淀粉共轭物及其制备方法，所述羟基烷基淀粉共轭物包括羟基烷基淀粉衍生物和细胞毒素药物，所述细胞毒素药物包括至少一个主要羟基基团，其中羟基烷基淀粉通过所述主要羟基基团与细胞毒素药物连接。本发明的共轭物具有以下式子的结构：HAS'(-L-M)n，其中M是细胞毒素药物的残基，L是连接基团，HAS'是羟基烷基淀粉衍生物的残基，n大于等于1，且羟基烷基淀粉衍生物具有平均分子量(MW)高于肾小球阈值且摩尔取代(MS)在0.6至1.5范围内。
• Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity
  申请人：Yoshida Hiroshi

  公开号：US20090143356A1

  公开（公告）日：2009-06-04

  Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. (wherein R 1 is hydrogen or lower alkyl; X is lower alkylene etc.; R 2 is optionally substituted aryl; R 3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R 4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B 1 and B 2 are such that any one of them is CR 20 R 21 , and the other is NR 22 and, in this case, there is no broken line. When B 2 is NR 22 , R 4 and R 22 may be connected together to form an optionally substituted heterocycle; When B 2 is CHR 21 , R 4 and R 21 may be connected together to form an optionally substituted heterocycle. Alternatively, B 1 and B 2 are independently C, CR 23 or N and, in this case, B 1 and B 2 may be taken together to form a heterocycle. R 20 , R 21 , R 22 and R 23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)

  提供具有抗病毒活性的新化合物，特别是具有HIV整合酶抑制活性的化合物，并提供一种药物组合物，特别是一种抗HIV剂。(其中，R1为氢或低碳基；X为低碳基亚烷等；R2为可选取代芳基；R3为氢、卤素、羟基、可选取代低碳基等；R4为氢、可选取代低碳基、可选取代环烷基、可选取代环烷基低碳基、可选取代芳基、可选取代芳基低碳基、可选取代杂环基、可选取代杂环低碳基等；断线表示键的存在或不存在；B1和B2是这样的，其中任何一个是CR20R21，另一个是NR22，此时没有断线。当B2为NR22时，R4和R22可以连接在一起形成可选取代的杂环；当B2为CHR21时，R4和R21可以连接在一起形成可选取代的杂环。或者，B1和B2分别是C、CR23或N，此时B1和B2可以连接在一起形成杂环。R20、R21、R22和R23分别为氢、可选取代低碳基、可选取代环烷基、可选取代环烷基低碳基等。